Last reviewed · How we verify
Insulin human/Novolin® 30R
Insulin human binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Insulin human binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin human/Novolin® 30R |
|---|---|
| Sponsor | Sanofi |
| Drug class | Insulin (human recombinant) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin human is a recombinant form of endogenous human insulin that mimics the body's natural insulin secretion. Novolin® 30R is a biphasic insulin preparation containing 30% soluble (rapid-acting) insulin and 70% isophane (intermediate-acting) insulin, providing both immediate and sustained glucose-lowering effects. It works by binding to insulin receptors on muscle, fat, and liver cells to facilitate glucose transport into cells and promote anabolic metabolism.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin human/Novolin® 30R CI brief — competitive landscape report
- Insulin human/Novolin® 30R updates RSS · CI watch RSS
- Sanofi portfolio CI